Bloomberg Law
May 12, 2020, 8:24 PMUpdated: May 12, 2020, 9:12 PM

Gilead Gives Royalty-Free Remdesivir Licenses to Five Drugmakers (1)

Valerie Bauman
Valerie Bauman

Gilead Sciences Inc. is licensing its potential Covid-19 treatment, remdesivir, to five generic drug manufacturers in India and Pakistan to speed supply chain development and help meet anticipated demand.

The company on Tuesday announced it signed non-exclusive, voluntary licensing agreements for the drug, which it originally developed in 2010 to treat Ebola.

The companies are Cipla Ltd., Ferozsons Laboratories, Hetero Labs Ltd., Jubilant Lifesciences, and Mylan. They will be able to produce the drug without paying Gilead royalties until the World Health Organization declares the end of the pandemic or until another drug or vaccine is approved to treat or ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.